How effective is Glasdegib?

Glasdegib is a new treatment for patients with newly diagnosed acute myeloid leukemia (AML). Based on the results of the multi-center, open-label, randomized study BRIGHT AML 1003, the drug's effectiveness in specific populations has been significantly verified. The study included 115 newly diagnosed AML patients who met at least one of the following criteria: age 75 years and older, severe heart disease, baseline performance status 2, or baseline serum creatinine greater than 1.3 mg/dL. The patients were randomly divided into two groups, with 77 receiving glasgiib plus low-dose cytarabine (LDAC) and 38 receiving LDAC alone.

With a median follow-up time of 20 months, the study results showed that the median survival time of the combination treatment group with Glasgib and LDAC was 8.3 months, while the median survival time of the LDAC alone group was 4.3 months. This showed that the combined use of Glasgib significantly improved the survival rate of patients, with a hazard ratio (HR) of 0.46 and statistical significance (p=0.0002). In addition, another study involving 116 patients who were unable to receive standard chemotherapy also found that Glasgib combined with low-dose cytarabine could prolong patients' lives, further supporting its potential for clinical application.

In summary, Glassgib has shown good efficacy in the treatment of elderly patients with newly diagnosed AML and significantly improved the overall survival rate. Because of its effectiveness in targeting specific high-risk patient groups, the drug offers clinicians a new option, especially when patients are unable to receive traditional chemotherapy due to age or other health conditions. However, despite the remarkable efficacy, attention still needs to be paid to monitoring side effects in patients in clinical practice to ensure the safety and tolerability of the treatment.

References:https://www.fda.gov/drugs/fda-approves-glasdegib-aml-adults-age-75-or-older-or-who-have-comorbidities